-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
FEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
IQVIA AI Assistant
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Meet the IQVIA AI Assistant
Your new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSBlog
Alzheimer's: On the threshold of change
Jul 12, 2017
The growing need to treat and prevent AD is spurring new research, but healthcare industry stakeholders need to work collaboratively if we are going to successfully bring groundbreaking treatments to market.
Alzheimer’s Disease (AD) has become an international healthcare crisis, spurring some of the greatest minds in healthcare to think more holistically about how to tackle this devastating disease. The disease affects an estimated 5.5 million Americans and is growing as our population ages; the prevalence of AD is expected triple to more than 14 million U.S. patients by 2050.
Billions have been spent on promising drug development projects over the past two decades, yielding precious few treatments that only target symptoms, and ultimately fail to slow progression.
Although the crisis is growing, so is the momentum for change. There is a renewed urgency to develop innovative drugs that treat, cure, or prevent Alzheimer’s. This passion is sparking new collaborations between patient communities, physicians, and other key stakeholders. Such collaborations are the key to finding and successfully implementing innovative solutions that address the massive unmet medical need.
Is the healthcare industry prepared to capture the opportunity and spark real change to the treatment paradigm? Our most recent white paper, A Call to Action: Alzheimer’s Disease on the Threshold of Change, identifies the five key challenges the industry will need to address to turn aspirations into action
- Identifying patients
- Understanding the full patient population
- Expanding the diagnostic infrastructure
- Transforming the treatment paradigm
- Affording the cost of care
Moving Alzheimer’s treatment forward will require significant system-wide infrastructure investment akin to the development of oncology clinics and screening initiatives that have led to the current scale of oncology treatment and diagnosis today.
A new treatment paradigm
The time to start thinking about the impact of new treatments – and the subsequent solutions – is now. Reimbursement and funding already present clear and present pain points. Currently, payer spending for drug costs associated with Alzheimer’s is a relatively modest slice of the total costs, which are now nearly $260B. Innovative new treatments are likely to be expensive, adding significantly to these totals. A single drug at $18,500 per patient annually, for example, would result in ~$30B in annual drug costs if used in clinical stage patients in the U.S. alone. If we include prodromal stage patients, those with initial symptoms of deteriorating memory that still function independently, overall spending on Alzheimer’s would almost double to ~$55B – and that doesn’t include related healthcare costs.
Despite the clinical and financial challenges, proactive industry leaders have an opportunity to be at the forefront of supporting the successful implementation of new Alzheimer’s treatments, helping to ensure new treatments are commercially successful, effective, affordable, and make a meaningful impact to patient’s lives. For more details on each of these challenges and the implications for clinical research and commercialization strategies, the full paper can be downloaded here.